Stay updated on CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial
Sign up to get notified when there's something new on the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page.

Latest updates to the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page
- Check3 days agoChange DetectedVersion bump from v3.0.1 to v3.0.2 and removal of the 'Back to Top' element; no substantive changes to core content or pricing.SummaryDifference0.2%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%
- Check17 days agoChange DetectedThe web page has been updated to include specific facility names and locations, particularly highlighting Seoul, South Korea, and has added a significant reference to a recent study on infliximab in rheumatoid arthritis. Additionally, there are updates to the categorization of proteins and antibodies relevant to the content.SummaryDifference4%
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12, indicating a revision in the content.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page.